New drug A3907 tested for rare liver disease PSC
NCT ID NCT05642468
First seen May 10, 2026 · Last updated May 13, 2026 · Updated 1 time
Summary
This study tested a drug called A3907 in 18 adults with primary sclerosing cholangitis (PSC), a rare liver disease. The main goal was to see if the drug is safe and tolerable. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
-
ASST di Monza - Azienda Ospedaliera San Gerardo
Monza, 20900, Italy
-
Azienda Ospedale Università Padova
Padova, 35128, Italy
-
Centrum Medyczne INTER-MED
Częstochowa, Poland
-
Hopital Saint Antoine
Paris, 75012, France
-
Hospital Clinic de Barcelona
Barcelona, 8036, Spain
-
ID Clinic Arkadiusz Pisula
Mysłowice, Poland
-
Uniwersyteckie Centrum Kliniczne im. Prof. Kornela Gibinskiego
Katowice, Poland
Conditions
Explore the condition pages connected to this study.